HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Barbara L Parsons Selected Research

Neoplasms (Cancer)

10/2021Assessment of Clonal Expansion Using CarcSeq Measurement of Lung Cancer Driver Mutations and Correlation With Mouse Strain- and Sex-Related Incidence of Spontaneous Lung Neoplasia.
1/2021Cross-oncopanel study reveals high sensitivity and accuracy with overall analytical performance depending on genomic regions.
11/2020Quantification of cancer driver mutations in human breast and lung DNA using targeted, error-corrected CarcSeq.
1/2020Rationale and Roadmap for Developing Panels of Hotspot Cancer Driver Gene Mutations as Biomarkers of Cancer Risk.
1/2020Outgrowth of erlotinib-resistant subpopulations recapitulated in patient-derived lung tumor spheroids and organoids.
1/2020ACB-PCR Quantification of Low-Frequency Hotspot Cancer-Driver Mutations.
7/2018Multiclonal tumor origin: Evidence and implications.
1/2017Variation in organ-specific PIK3CA and KRAS mutant levels in normal human tissues correlates with mutation prevalence in corresponding carcinomas.
1/2016Breast Cancer Heterogeneity Examined by High-Sensitivity Quantification of PIK3CA, KRAS, HRAS, and BRAF Mutations in Normal Breast and Ductal Carcinomas.
8/2015Quantification of Kras mutant fraction in the lung DNA of mice exposed to aerosolized particulate vanadium pentoxide by inhalation.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Barbara L Parsons Research Topics

Disease

34Neoplasms (Cancer)
10/2021 - 06/2002
9Carcinogenesis
07/2018 - 11/2006
3Lung Neoplasms (Lung Cancer)
10/2021 - 03/2013
3Adenoma (Adenomas)
10/2021 - 05/2010
3Body Weight (Weight, Body)
10/2013 - 06/2011
3Colonic Neoplasms (Colon Cancer)
04/2013 - 12/2009
2Carcinoma (Carcinomatosis)
10/2021 - 05/2010
1Breast Neoplasms (Breast Cancer)
01/2021
1Bronchiolo-Alveolar Adenocarcinoma (Adenocarcinoma, Bronchiolo Alveolar)
08/2015
1Adenocarcinoma of Lung
03/2015
1Inflammation (Inflammations)
12/2014
1Anaplastic Thyroid Carcinoma
02/2014
1Necrosis
02/2014
1Colorectal Neoplasms (Colorectal Cancer)
04/2013
1Pathologic Processes
06/2011
1Neuroblastoma
04/2011
1Skin Neoplasms (Skin Cancer)
08/2008

Drug/Important Bio-Agent (IBA)

14Codon (Codons)IBA
10/2021 - 06/2002
10DNA (Deoxyribonucleic Acid)IBA
10/2021 - 06/2002
9Biomarkers (Surrogate Marker)IBA
01/2021 - 04/2005
5GATIBA
03/2015 - 11/2006
4CarcinogensIBA
10/2013 - 06/2011
3DNA AdductsIBA
08/2012 - 03/2010
2ErbB Receptors (EGF Receptor)IBA
01/2020 - 04/2013
2aristolochic acid I (aristolochic acid)IBA
08/2012 - 09/2011
1Phosphotransferases (Kinase)IBA
01/2020
1Erlotinib Hydrochloride (CP 358,774)FDA Link
01/2020
1vanadium pentoxideIBA
08/2015
1AerosolsIBA
08/2015
1AsbestosIBA
12/2014
1Mineral Fibers (Mineral Fiber)IBA
12/2014
1furanIBA
10/2013
1Drinking WaterIBA
06/2013
1chromium hexavalent ionIBA
06/2013
1sodium bichromate (sodium dichromate)IBA
06/2013
1Monoclonal AntibodiesIBA
04/2013
1AzoxymethaneIBA
06/2011
1naphthaleneIBA
04/2011
1Benzo(a)pyreneIBA
10/2010
1MutagensIBA
10/2010
1Formaldehyde (Formol)FDA Link
07/2010
1Tumor Biomarkers (Tumor Markers)IBA
05/2010
14-biphenylamineIBA
04/2005

Therapy/Procedure

8Therapeutics
01/2020 - 07/2012
2Aftercare (After-Treatment)
06/2011 - 04/2005
1Precision Medicine
07/2018